Five milligrams of rivaroxaban per day added to a patient’s standard therapy for heart failure (HF) and coronary artery disease (CAD) could reduce that patient’s risk of future thromboembolic events, researchers reported in JAMA Cardiology April 24.

Pennsylvania-based health company Orchestra BioMed has obtained FDA breakthrough device designation for its Virtue sirolimus-eluting balloon (SEB), according to a statement issued April 24.

Around a quarter of heart patients who undergo percutaneous coronary intervention (PCI) are readmitted to the hospital for unplanned reasons within six months of their procedure, researchers report in JACC: Cardiovascular Interventions.

The FDA’s Circulatory System Devices Panel of the Medical Devices Advisory Committee will meet in mid-June to discuss recent controversies and safety practices surrounding paclitaxel-coated and -eluting medical devices, according to a notice posted April 22.

Boston Scientific’s LOTUS Edge Aortic Valve System was cleared by the FDA April 23 for use in high-risk surgical candidates with severe aortic stenosis.

The American Academy of Pediatrics’ (AAP) updated blood pressure guidelines classify more kids in higher BP categories and can more accurately predict which children are prone to heart disease later in life, an extensive analysis of the Bogalusa Heart Study has found.

Torrent Pharmaceuticals Limited has expanded its recent recall of blood pressure-regulating losartan tablets to include an additional 104 lots of the drugs, the company announced April 18.

Eating a late dinner and skipping breakfast could raise heart patients’ risk of a repeat MI or death by up to fivefold, according to research published in the European Journal of Preventive Cardiology April 17.